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BACKGROUND: Circular RNAs (circRNAs) have recently
been described as novel noncoding regulators of gene
expression. They are detectable in the blood of patients
with acute kidney injury. We tested whether circRNAs
were present in urine and could serve as new predictors of
outcome in renal transplant patients with acute rejection.
METHODS: A global circRNA expression analysis using
RNA from urine of patients with acute T cell-mediated
renal allograft rejection and control transplant patients
was performed. Dysregulated circRNAs were confirmed
in a cohort of 62 patients with acute rejection, 10 patients
after successful antirejection therapy, 18 control trans-
plant patients without rejection, and 13 stable transplant
patients with urinary tract infection.
RESULTS: A global screen revealed several circRNAs to be
altered in urine of patients with acute rejection. Concen-
trations of 2 circRNAs including hsa_circ_0001334 and
hsa_circ_0071475 were significantly increased. These
were validated in the whole cohort of patients.
hsa_circ_0001334 was upregulated in patients with acute
rejection compared with controls. Concentrations of
hsa_circ_0001334 normalized in patients with acute
rejection following successful antirejection therapy.
hsa_circ_0001334 was associated with higher decline in
glomerular filtration rate 1 year after transplantation.
CONCLUSIONS: CircRNA concentrations are significantly
dysregulated in patients with acute rejection at subclinical
time points. Urinary hsa_circ_0001334 is a novel biomarker
of acute kidney rejection, identifying patients with acute
rejection and predicting loss of kidney function.
© 2019 American Association for Clinical Chemistry
Chronic allograft dysfunction is a major contributor to
impairment of long-term kidney function, graft loss, and
survival of patients (1 ). It is itself a consequence of acute
rejection episodes of renal allografts (1 ). The use of po-
tent immunosuppressants has steeply reduced the inci-
dence of acute rejection (2 ). Timely detection of acute
rejections in patients after kidney transplantation is of
utmost importance to initiate an immunosuppressive an-
tirejection therapy without delay, thereby preventing se-
vere injury of the graft. Histological assessment of kidney
biopsy specimens is still necessary and most precise in the
diagnosis of acute rejection episodes. It also enables iden-
tification of subclinical rejection, which is defined by
histological lesions without a change in kidney function
parameters, e.g., serum creatinine (3, 4 ). The invasive
nature of kidney biopsies and their associated potentially
severely harmful side effects remain a challenge as far as
patient safety is concerned. Kidney function may be as-
sessed noninvasively by the use of creatinine in blood
samples. However, creatinine assessment is sometimes
unreliable in precisely identifying a patient’s kidney func-
tion because of its dependency on muscle mass. More-
over, increases in creatinine concentrations occur with a
time lag and at later stages with already progressed kidney
damage and, therefore, are not sufficient to detect early
rejection (5 ). Thus, novel biomarkers, combining clini-
cal sensitivity, specificity, and noninvasiveness, are de-
sired. A large part of the human genome (90%) is tran-
scribed into RNA transcripts without protein-coding
potential (6 ). Based on their size, these so-called noncod-
ing RNAs (ncRNAs)4 are arbitrarily separated into long
ncRNAs (lncRNAs, 200 nucleotides) and small ncRNAs
(200 nucleotides). MicroRNAs (miRNAs) and lncRNAs
have also been investigated (7–10). miRNA activity has
been shown to be affected by the presence of miRNA
sponge transcripts, the so-called competing endogenous
RNA. Circular RNAs (circRNAs), which are themselves
considered lncRNAs, are part of the aforementioned
competing endogenous RNA. They are endogenously ex-
pressed as single-stranded, covalently closed circular mol-
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Cantonal Hospital, Frauenfeld, Switzerland; 3 Division of Nephrology andHypertension,
Hanover Medical School, Hanover, Germany.
* Address correspondence to: M.K. at Division of Nephrology, University Hospital Zürich,
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ecules (11 ). CircRNAs are secreted into the bloodstream
with a remarkable stability owing to resistance to exonu-
cleases through circularization. We recently performed a
study investigating the presence of circRNAs in blood of
patients with acute kidney injury (12 ). However, because
of its accessibility, urine is the ideal specimen to detect
intrarenal changes. Therefore, we investigated here the
predictive nature of circRNAs in urine of renal transplant
patients with acute T cell-mediated rejection concerning
acute rejection (primary outcome measure) and loss of
glomerular filtration rate at 1 year after transplantation
(secondary outcome measure).
Materials and Methods
PATIENTS AND SAMPLE COLLECTION
The study was approved by the Ethical Committee of the
Hanover Medical School. All patients received and
signed written informed consent. At our transplant cen-
ter, renal protocol biopsies are regularly performed after 6
weeks, 3 and 6 months following kidney or combined
kidney/pancreas transplantation. Midstream spot-urine
samples were collected immediately before biopsy collec-
tion and subsequently frozen at 80 °C. Routine analy-
ses of fresh urine samples include determination of pro-
tein concentration and screening for hematuria and
leukocyturia by dipstick analysis and microscopic inspec-
tion. The available urine samples were divided into 2
groups according to the files from patients who partici-
pated in the protocol biopsy program: (a) transplant pa-
tients with biopsy-proven acute cellular rejection (n 
62) and (b) transplant patients with stable kidney func-
tion without evidence of acute rejection (n  31) as
controls. Fifty-one patients presented with subclinical re-
jection, which was defined as a biopsy-proven rejection
without changes in serum creatinine. Eleven patients had
a clinically detectable rejection (change in serum creati-
nine by 20%). In total, acute cellular rejection could be
detected in 20 urine samples from patients at 6 weeks, 28
urine samples at 3 months, and 14 urine samples at 6
months after kidney transplantation. Forty-four patients
presented with Banff IA rejection, 9 with Banff IB, 8 with
Banff 2A, and 1 patient with Banff 2B rejection. In ad-
dition, 10 urine samples after successful antirejection
therapy of patients with acute rejection were also ana-
lyzed. Interpretation of biopsies was performed accord-
ing to the updated Banff 2009 classification (13 ). Glo-
merular filtration rate (GFR) was calculated according to
the Cockcroft–Gault formula. All samples were pro-
cessed within 4 h.
A detailed description of the study outcomes and
statistical analysis, RNA isolation, circRNA transcrip-
tome analysis, and circRNA validation are provided in
the Materials and Methods file found in the Data Sup-
plement that accompanies the online version of this arti-
cle at http://www.clinchem.org/content/vol65/issue10.
The most highly dysregulated circRNAs are shown in
Table 1 of the online Data Supplement.
Results
circRNA EXPRESSION ANALYSIS IN URINE
To test the predictive value of urinary circRNAs in renal
transplant patients with acute T cell-mediated rejection,
we performed a genome-wide circRNA expression anal-
ysis in urine of patients with T cell-mediated rejection
(n  9) and age-matched control transplant patients with
stable function (n  9). In total, 5119 circRNAs were
detected and 363 circRNAs with signal intensities 4
were differentially expressed (see Table 1 in the online
Data Supplement). Fig. 1 shows a heatmap of the most
strongly differentially expressed and subsequently hierar-
chically clustered circRNAs. A distinct expression signa-
ture of circRNAs could clearly detect rejection patients.
The variation in circRNA expression is displayed as a
scatter plot in Fig. 2A. Fold changes in relation to P
values were visualized as a volcano plot in Fig. 2B. To
identify promising circRNA candidates for subsequent
biomarker analysis, we focused on candidates with high
signal intensities in all groups to guarantee stable detec-
tion but also on high differential expression. CircRNA
candidates hsa_circ_0071475 and hsa_circ_0001334
were selected for further validation studies in the whole
cohort (marked in Fig. 2, A and B). hsa_circ_0071475
was chosen specifically because of its high fold change,
and hsa_circ_0001334 was selected because of its addi-
tional high signal intensity in all groups. An overview of
the 20 most strongly upregulated circRNAs with signal
intensities 6 is summarized in Table 2 of the online
Data Supplement, and the top 20 downregulated cir-
cRNAs with a signal intensity 6 are displayed in Table
3 of the online Data Supplement.
circRNA VALIDATION IN URINE
To investigate the detectability of dysregulated urinary
circRNAs, we assessed the 20 most highly dysregulated
circRNAs using RNA isolated from urine of patients with
transplant rejection in agarose gel electrophoresis. Here,
we found 2 circRNAs to display specific bands of correct
size, including hsa_circ_0071475 and hsa_circ_0001334.
We then performed real-time PCR analysis in a subset of
patients with acute T cell-mediated rejection (n  10).
These 2 novel transcripts showed clean amplification
curves and specific curves in melting curve analysis and
were undetectable in water controls without template.
To ascertain that transcripts were specifically detected in
urine, we sequenced transcripts in these patients after
PCR amplification, which confirmed that circRNAs
were correctly amplified and detectable.





























































































Primer sequences of tested circRNAs are given in
Table 4 of the online Data Supplement.
hsa_circ_0001334 IS A NOVEL BIOMARKER OF ACUTE T
CELL-MEDIATED REJECTION
We next compared the concentrations of identified tran-
scripts hsa_circ_0071475 and hsa_circ_0001334 be-
tween 18 samples from stable controls without rejection,
13 transplant patients with urinary tract infection (dis-
ease controls), 62 samples of patients with acute T cell-
mediated rejection, and 10 samples from patients follow-
ing successful antirejection therapy (these samples were
chosen from the 62 samples with acute rejection at a
different time point after transplantation). As shown in
Fig. 3A, hsa_circ_0071475 could not be confirmed to be
differentially regulated in patients with acute T cell-
Fig. 1. Whole-genome circRNA expression analysis: hierarchical cluster of dysregulated circRNAs in urine from patients with T
cell-mediated acute renal allograft rejection vs control transplant patients with stable kidney function.
Downregulated circRNAs are depicted in green and upregulated in red; 2 investigated circRNAs in the whole cohort aremarked. Each column
represents pooled RNA from 3 patients.
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Fig. 2. Scatter plot (A) and volcano plot analysis (B) of dysregulated circRNAs in urine of patients with acute rejection and stable
controls.
Identified circRNA are further marked: hsa_circ_0001334 (black circle) and hsa_circ_0071475 (black square). Gray color represents nonsig-
nificantly altered transcripts; red color represents significantly altered transcripts.





























































































mediated rejection. The concentrations of the second
candidate hsa_circ_0001334 were significantly increased
(P  0.0001) in patients with acute T cell-mediated re-
jection compared with stable transplant controls without
signs of rejection (Fig. 3B). In addition, it was not signif-
icantly different in kidney transplant patients with uri-
nary tract infection, indicating its clinical specificity as a
biomarker of acute rejection episodes (Fig. 3B). More-
over, hsa_circ_0001334 concentrations normalized in 10
patients with acute T cell-mediated rejection after suc-
cessful antirejection therapy (Fig. 3B here and also Fig. 1
in the online Data Supplement). To assess the biomarker
performance of hsa_circ_0001334, we performed an
ROC curve analysis (Fig. 4A), which indicated an area
under the curve of 0.85 (P  0.0001). A cut point of 2.41
was associated with a clinical sensitivity of 70.11% (95%
CI, 59.35%–79.46%) and a clinical specificity of
92.31% (95% CI, 63.97%–99.81%) and a likelihood
ratio of 9.115. The positive predictive value of this cut
point was calculated to be 98.39%, and the negative pre-
dictive value was 31.58%. Moreover, hsa_circ_0001334
(r  0.4; P  0.01) was significantly associated with
decline in GFR 6 weeks after transplantation compared
with 1 year after transplantation (Fig. 4B), supporting a
higher GFR loss in patients with high concentrations of
urinary hsa_circ_0001334. Fig. 2A in the online Data
Supplement shows the changes in serum creatinine con-
centrations before and at the time of rejection. Fifty-one
patients presented with subclinical rejection (no changes
in serum creatinine), and 11 patients presented with clin-
Fig. 3. Validation of urinary circRNA concentrations in the
whole cohort of patients.
(A), Concentrations of hsa_circ_0071475 in patients with acute T
cell-mediated rejection compared with control patients (CTL) with
stable transplant function and transplant patients with urinary
tract infection (UTI) as well as in patients after successful antirejec-
tion therapy. (B), Concentrations ofhsa_circ_0001334 in patients
with acute T cell-mediated rejection compared with control pa-
tients with stable transplant function and transplant patients with
UTI as well as in patients after successful antirejection therapy.
**P< 0.01; ***P< 0.001; ****P< 0.0001.
Fig. 4. Sensitivity, specificity, and predictive value of hsa_
circ_0001334.
(A), ROC curve analysis of patients with acute T cell-mediated re-
jection compared with stable control patients regarding urinary
hsa_circ_0001334. Urinary hsa_circ_0001334 predicts long-
term outcome of renal transplant patients with acute rejection.
(B), High hsa_circ_0001334 concentrations (r = 0.4; P = 0.01)
were significantly associated with decline in GFR 1 year after
transplantation.
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ically detectable rejection (changes in serum creatinine).
hsa_circ_0001334 detects patients with subclinical rejec-
tion, which would have been missed by routine serum
creatinine measurements (see Fig. 2B in the online Data
Supplement). Therefore, we propose hsa_circ_0001334
as a marker of acute rejection, which is superior to mea-
suring serum creatinine changes in patients.
hsa_circ_0001334 SPONGES hsa-miR-4459, hsa-miR-665, hsa-
miR-6514-3p, hsa-miR-4739, AND hsa-miR-6893-5p
CircRNAs are involved in diverse biological functions.
One of the most important functions is characterized by
sponging and sequestering miRNAs (11 ). Therefore, we
tested whether hsa_circ_0001334 contained binding sites
for miRNAs. We used the bioinformatic TargetScan and
miRanda algorithms and identified binding sites for 5
different miRNAs: hsa-miR-4459, hsa-miR-665, hsa-
miR-6514-3p, hsa-miR-4739, and hsa-miR-6893-5p (see
Fig. 3 in the online Data Supplement). More specifically,
hsa_circ_0001334 contained 8 binding sites for hsa-miR-
4459 and 6 binding sites for hsa-miR-665, hsa-miR-
6514-3p, hsa-miR-4739, and hsa-miR-6893-5p, respec-
tively (see Fig. 3, A-E, in the online Data Supplement).
Discussion
We performed a clinical evaluation of urinary circRNAs
in patients with transplant- associated kidney disease.
Our results are as follows. First, the detection of
circRNAs in urine was feasible. Second, a variety of
circRNAs were significantly (P  0.05) dysregulated in
urine of transplant patients. Third, in a validation cohort
the concentration of transcript hsa_circ_0001334 was
up-regulated in patients with acute rejection compared
with controls with stable graft function and disease con-
trols with urinary tract infection. Although the fold
change of hsa_circ_0071475 was larger than the one of
our final candidate hsa_circ_0001334, the signal intensi-
ties of hsa_circ_0071475 were much lower than the ones
of hsa_circ_0001334 (see Tables 1 and 2 in the online
Data Supplement). Consequently, we found that a high
signal intensity as shown for hsa_circ_0001334 was of
much higher diagnostic value because differentiation of
patients and controls was constantly guaranteed. Fourth,
the concentrations of hsa_circ_0001334 were normalized
in patients with acute rejection following successful
antirejection therapy. Fifth, the concentrations of hsa_
circ_0001334 were predictive concerning subsequent
loss of kidney function.
Our study demonstrates that urinary circRNAs in
patients with any type of kidney disease can be stably
isolated and detected. As previously shown for miR-
NAs (14, 15 ) and lncRNAs (16, 17 ), a stable control
or “housekeeping” circRNA has not been defined in
body fluids of patients. Therefore, we supplemented
recombinant Caenorhabditis elegans–miR-39 to urine
samples during the RNA isolation process to normal-
ize for potential differences in RNA isolation effi-
ciency and relate concentrations of urinary circRNAs
to these levels of known concentration. This approach
was previously shown for blood-derived circRNAs
(12 ).
In search of adequate biomarkers of early detec-
tion of acute renal allograft rejection, an extensive
body of literature has been produced investigating cir-
culating plasma or serum concentrations as well as
urinary concentrations of adhesion molecules, cyto-
kines, mRNAs, and lymphocyte expression levels (e.g.,
perforin, granzyme B, and FAS ligand) (18 ). How-
ever, none of these markers have entered routine clin-
ical practice so far.
More than 90% of the human genome is transcribed
into RNA transcripts without protein-coding potential
(10 ). Small RNAs have been the subject of increased
research initiatives as regulators of disease and biomarkers
of disease initiation and response to therapy (7–10, 14–
17). On the contrary, the focus has only recently shifted
toward analysis of circRNA dysregulation. Their func-
tion and biomarker potential are largely unknown to
date. CircRNAs share the potential of gene regulation as
previously shown for miRNAs and lncRNAs (19–21).
CircRNAs have been described to be abundant in the
eukaryotic transcriptome and to pose intricate functions.
CircRNAs have a length of approximately 100 nucleo-
tides and are secreted into exosomes (22 ). CircRNAs are
generated through a mechanism known as back-splicing
“tail” to “head,” whereby an exon at the 3 end of a gene
is back-spliced to an exon at the 5 end of the gene result-
ing in a circRNA form (19, 20 ). They can arise mainly
from exons, but circRNAs deriving from intergenic or
intragenic and intronic regions as well as antisense se-
quences have been reported (19, 20 ). Owing to their
circular structure and the absence of a 5 cap, it is currently
believed that circRNAs are not translated into protein
(23 ). CircRNAs are believed to have diverse functions,
the most important likely being the sponging and seques-
tering of miRNAs (22, 24 ). This interaction might only
be observed in circRNAs with a high number of binding
sites for a specific miRNA, such as ciRs-7 (circular RNA
sponge for miR-7), for which an excess of 70 conserved
miR-7 target sites has been reported (24 ). CircRNAs
show a highly enhanced half-life as compared with their
linear counterparts. This is because of their circular struc-
ture, which results in lessened susceptibility to exonu-
cleases (22 ). This stability may offer an improved suit-
ability as stable biomarkers in body fluids.
We previously identified ciRs-126 (circular RNA
sponge of miR-126) as a promising new circRNA bio-
marker in the diagnosis and prognosis of patients with acute
kidney injury (12). We present here a study on the expres-





























































































sion of circRNAs in urine of transplant patients. The use of
urinary biomarkers is a huge advantage in the care of pa-
tients with kidney disease because they can be easily assessed
in a timely manner without exposing patients to harmful
side effects of the kidney biopsy procedure. Given the high
clinical sensitivity and specificity as a biomarker, assessment
of urinary concentrations of hsa_circ_0001334 might be
considered as an improvement of patient surveillance fol-
lowing kidney transplantation.
There are several distinct possible sources of circu-
lating circRNAs. In hematopoietic cells including pro-
genitors and differentiated myeloid and lymphoid cells,
circRNA expression can be cell-specific and increases
during cellular maturation (25 ). Interestingly, enucle-
ated cells such as red blood cells and platelets appear to
express higher concentrations of circRNAs as compared
with nucleated hematopoietic cells (26, 27 ). Platelets, in
particular, express the highest number of circRNAs, al-
most twice as much as red blood cells and 5 times more
than granulocytes (26, 27 ). Small vesicles including exo-
somes carry large amounts of circRNAs (28 ). The bio-
marker potential of circRNAs has recently been demon-
strated for a variety of patient cohorts, including
atherosclerosis (29 ), disorders of the central nervous sys-
tem (30 ), and cancers (28, 31 ).
There are important limitations to our study: We do
not provide molecular insights into the underlying mech-
anisms of urinary circRNA release. Our study represents
Table 1. Demographic, clinical, and laboratory characteristics of patients.
Total No rejection Rejection P value
Number of patients 93 31 62 0.2
Male, n (%) 54 (58) 18 36
Female, n (%) 39 (42) 13 26
Age, years (minimum–maximum) 51 (18–73) 53 (18–68) 51 (21–73) 0.5
Primary transplant, n 81 25 56 0.2
Additional pancreas Txa, n 3 2 1 0.3
Type of allograft, n 0.4
Deceased donor 80 28 52
Living donor 13 3 10
Initial graft function, n 72 23 49 0.6
Need for HD post-Tx, n 20 6 14 0.8
HLA mismatch, n
Locus A (0/1/2) 48/35/10 18/8/5 30/27/5 0.2
Locus B (0/1/2) 40/37/16 17/10/4 23/27/12 0.3
Locus DR (0/1/2) 32/45/16 18/12/1 14/33/15 0.001b
Donor CMV status, n (positive/negative) 53/40 11/20 42/20 0.004b
Type of RRT before Tx (HD/PD/preemptive) 83/8/2 28/3/0 55/5/2 0.6
Diabetes mellitus 0.5
Type 1 4 2 2
Type 2 5 1 4
Hyperparathyroidism before Tx 28 5 23 0.05
Initial immunosuppression, n
Cyclosporine 73 26 47 0.4
Tacrolimus 17 5 12 0.8
Mycophenolate mofetil 55 19 36 0.8
Azathioprine 1 0 1 0.6
Sirolimus 7 1 6 0.4
Steroids 88 30 58 0.7
Preformed antibodies (>1%) 4 3 1 0.1
a Tx, transplant; HD, hemodialysis; CMV, cytomegalovirus; RRT, renal replacement therapy; PD, peritoneal dialysis; HLA, human leukocyte antigen.
b p< 0.01.
Urinary circRNAs in Acute Rejection





























































































a single center experience with a limited number of pa-
tients. Larger independent cohorts are necessary to vali-
date our findings.
In conclusion, we analyzed the potential of urinary
circRNAs as a marker of acute rejection in kidney trans-
plant patients. Urinary circRNAs can be stably detected
in urine. We identified hsa_circ_0001334 as a marker of
acute rejection and predictor of subsequent loss of graft
function. The fact that hsa_circ_0001334 increases spe-
cifically with the development of acute rejection and
normalizes to concentrations of stable controls with suc-
cessful antirejection therapy provides evidence for
hsa_circ_0001334 as a novel biomarker of acute rejection
with the potential for clinical application to monitor re-
jection episodes without the potential harms associated
with an invasive renal allograft biopsy.
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